Cargando…
Exenatide: A New Promising Antidiabetic Agent
Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the d...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883206/ https://www.ncbi.nlm.nih.gov/pubmed/20582183 http://dx.doi.org/10.4103/0250-474X.62228 |
_version_ | 1782182242856992768 |
---|---|
author | Chakraborti, C. K. |
author_facet | Chakraborti, C. K. |
author_sort | Chakraborti, C. K. |
collection | PubMed |
description | Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin. |
format | Text |
id | pubmed-2883206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-28832062010-06-25 Exenatide: A New Promising Antidiabetic Agent Chakraborti, C. K. Indian J Pharm Sci Review Article Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin. Medknow Publications 2010 /pmc/articles/PMC2883206/ /pubmed/20582183 http://dx.doi.org/10.4103/0250-474X.62228 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chakraborti, C. K. Exenatide: A New Promising Antidiabetic Agent |
title | Exenatide: A New Promising Antidiabetic Agent |
title_full | Exenatide: A New Promising Antidiabetic Agent |
title_fullStr | Exenatide: A New Promising Antidiabetic Agent |
title_full_unstemmed | Exenatide: A New Promising Antidiabetic Agent |
title_short | Exenatide: A New Promising Antidiabetic Agent |
title_sort | exenatide: a new promising antidiabetic agent |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883206/ https://www.ncbi.nlm.nih.gov/pubmed/20582183 http://dx.doi.org/10.4103/0250-474X.62228 |
work_keys_str_mv | AT chakrabortick exenatideanewpromisingantidiabeticagent |